Strong Uptake of Xywav and Epidiolex Drive Growth for Jazz Pharmaceuticals
We maintain our fair value estimate of $187 per share. Xywav (for excessive daytime sleepiness), Epidiolex (for childhood epilepsy), and Rylaze (for leukemia) have continued to be Jazz’s primary ...
BioSpace7h
How SpringWorks Took Pfizer’s Rare Disease Ghost Drug and Got It to Patients
SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...
BioSpace7h
How to Mine Biopharma’s IP Storeroom for Rare Disease Drugs, Just Like SpringWorks
SpringWorks Therapeutics is the perfect case study for rescuing a discontinued assets. It’s time to repeat the process for ...
STAT23h
Trump’s FDA navigates layoffs, exits, and a new hire
The Trump administration has started rehiring some of the FDA employees it fired last week, the latest chapter in a haphazard ...